Colitis

Gastroenterology·MeSH: Colitis, Ulcerative

Prevalence

263.0 / 100K

Incidence

9.0 / 100K/yr

95 drugs in development·46 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(17)
DrugCompany
abx464Abivax SA (ABVX)
ABX464Abivax SA (ABVX)
duvakitugSanofi (SNYNF)
duvakitugSanofi (SNY)
icotrokinraGH Research PLC (GHRS)
infliximabGH Research PLC (GHRS)
IV TulisokibartMerck & Co., Inc. (MRK)
Mirikizumab IVELI LILLY & Co (LLY)
Mirikizumab SCELI LILLY & Co (LLY)
ozanimodCELGENE CORP /DE/ (CELG)
ozanimodBRISTOL MYERS SQUIBB CO (BMY)
SC TulisokibartMerck & Co., Inc. (MRK)
tak-279Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
tak-279TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumabTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
VedolizumabAbbVie Inc. (ABBV)
vedolizumab scTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Phase 2(33)
DrugCompany
balinatunfibSanofi (SNY)
bertilimumabIMMUNE PHARMACEUTICALS INC (IMNP)
EltrekibartELI LILLY & Co (LLY)
emvistegrastGILEAD SCIENCES, INC. (GILD)
etrasimodPFIZER INC (PFE)
fxr314VivoSim Labs, INC. (VIVS)
JNJ-77242113Crinetics Pharmaceuticals, Inc. (CRNX)
LY4268989ELI LILLY & Co (LLY)
ly4395089ELI LILLY & Co (LLY)
mas825Novartis AG (NVS)
MAS825Novartis AG (NVS)
met642Metacrine, Inc. (MTCR)
MirikizumabELI LILLY & Co (LLY)
mirikizumab -ELI LILLY & Co (LLY)
morf-057Morphic Holding, Inc. (MORF)
nx-13AbbVie Inc. (ABBV)
nx-13Landos Biopharma, Inc. (LABP)
od-07656Odyssey Health, Inc. (ODYY)
pl8177PALATIN TECHNOLOGIES INC (PTN)
RosnilimabANAPTYSBIO, INC (ANAB)
sar442970Sanofi (SNY)
SAR442970Sanofi (SNY)
sar443122Sanofi (SNYNF)
sar443122Sanofi (SNY)
sar444336Sanofi (SNY)
sar444336Sanofi (SNYNF)
SER-287Seres Therapeutics, Inc. (MCRB)
SPY001Spyre Therapeutics, Inc. (SYRE)
SPY002Spyre Therapeutics, Inc. (SYRE)
SPY003Spyre Therapeutics, Inc. (SYRE)
tamuzimodVentyx Biosciences, Inc. (VTYX)
TulisokibartMerck & Co., Inc. (MRK)
vedolizumabOdyssey Health, Inc. (ODYY)
Phase 1/Phase 2(1)
DrugCompany
XmAb942Xencor Inc (XNCR)
Phase 4(12)
DrugCompany
golimumabGH Research PLC (GHRS)
RisankizumabAbbVie Inc. (ABBV)
teicoplaninSanofi (SNY)
vedolizumabTAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumabTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumabTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab ivTAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumab ivTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab ivTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab ivTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
vedolizumab scTAKEDA PHARMACEUTICAL CO LTD (TKPHF)
vedolizumab scTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Compare drugs

abrilada vs chlordiazepoxideabrilada vs donnatalabrilada vs Hadlima (SB5)

Frequently asked questions

How many drugs are in development for Colitis?

BioSniper tracks 95 drugs in development for Colitis across 46 companies.

How many clinical trials target Colitis?

There are 1 clinical trial targeting Colitis tracked by BioSniper.

What is the prevalence of Colitis?

The estimated prevalence of Colitis is approximately 263.0 per 100,000 population.

Deep-dive into Colitis

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis